Promethera: Liver Supply
Promethera: hepatic stem cells for liver genetic disorders and toxicology testing
A consistent shortage of human livers has limited the availability of the organs for transplantation and the ability for biomedical researchers to have a steady supply of hepatocytes for preclinical testing. Promethera Biosciences S.A. believes its human adult liver-derived mesenchymal stem cells can help solve both issues.
The company is developing the cells as a therapy for liver-related genetic disorders, and as a source of hepatocytes for preclinical metabolism and toxicology testing.
According to CEO Eric Halioua, more than 200 genetic disorders affect the liver, including